921 reports of this reaction
1.6% of all AMITRIPTYLINE HYDROCHLORIDE reports
#13 most reported adverse reaction
COGNITIVE DISORDER is the #13 most commonly reported adverse reaction for AMITRIPTYLINE HYDROCHLORIDE, manufactured by Advagen Pharma Ltd. There are 921 FDA adverse event reports linking AMITRIPTYLINE HYDROCHLORIDE to COGNITIVE DISORDER. This represents approximately 1.6% of all 56,602 adverse event reports for this drug.
Patients taking AMITRIPTYLINE HYDROCHLORIDE who experience cognitive disorder should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
COGNITIVE DISORDER is a less commonly reported adverse event for AMITRIPTYLINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to cognitive disorder, the following adverse reactions have been reported for AMITRIPTYLINE HYDROCHLORIDE:
The following drugs have also been linked to cognitive disorder in FDA adverse event reports:
COGNITIVE DISORDER has been reported as an adverse event in 921 FDA reports for AMITRIPTYLINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
COGNITIVE DISORDER accounts for approximately 1.6% of all adverse event reports for AMITRIPTYLINE HYDROCHLORIDE, making it a notable side effect.
If you experience cognitive disorder while taking AMITRIPTYLINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.